Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24121996 | 0.75 | NPC1 (0.39) | NPC1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL21067213 | 0.71 | ALDH1A1 (0.39) | NPC1ALDH1A1MAPTRAB9AHSD17B10 | |
| SCHEMBL21067265 | 0.67 | KDM4E (0.31) | HSD17B10 | |
| SCHEMBL31174800 | 0.64 | CYP11B2 (0.34) | ALDH1A1 | |
| SCHEMBL4561137 | 0.62 | GRM2 (0.31) | — | |
| SCHEMBL8352933 | 0.58 | IDO1 (0.38) | — | |
| SCHEMBL6629927 | 0.58 | ALDH1A1 (0.39) | NPC1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL13313508 | 0.58 | KDM4E (0.31) | NPC1RAB9A | |
| SCHEMBL20743849 | 0.57 | IDO1 (0.43) | — | |
| SCHEMBL20612512 | 0.57 | TBXAS1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766893-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2020-09-08 | — | — | US | disclosed |
| US-20190194189-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766893-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | PDE12, PDE3B, PDE5A | NPC1 2349/4885ALDH1A1 90/4885MAPT 300/4885 |
| US-20190194189-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | PDE12, PDE3B, PDE5A | NPC1 2349/4885ALDH1A1 90/4885MAPT 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.